TARIS Biomedical
TARIS Biomedical was a private Lexington, MA biopharmaceutical company founded in 2008 that developed a proprietary intravesical drug delivery platform for targeted bladder cancer treatment, particularly FGFR-mutated non-muscle-invasive bladder cancer. Acquired by Johnson & Johnson in 2019.
- Company typePrivate
- Founded2008
- HeadquartersLexington, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
TARIS Biomedical firmographics
Firmographics- Name
- TARIS Biomedical
- Website
- https://tarisbiomedical.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- TARIS Biomedical was a private Lexington, MA biopharmaceutical company founded in 2008 that developed a proprietary intravesical drug delivery platform for targeted bladder cancer treatment, particularly FGFR-mutated non-muscle-invasive bladder cancer. Acquired by Johnson & Johnson in 2019.
- Ownership category
- akta.pro rank
TARIS Biomedical industry classification
Industry- Product category
- Urologic Oncology Therapeutics
- NAICS
- Medicinal and Botanical Manufacturing (325411), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
- akta.pro secondary industry
- Urologic Oncology (HLAKAOAB)
Keywords
Where TARIS Biomedical is headquartered
LocationHeadquarters
- HQ city
- Lexington
- HQ country
- United States
- HQ region
- North America
Markets served
TARIS Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
TARIS Biomedical product offering
Product offeringCore offering
TARIS Biomedical developed a proprietary intravesical drug delivery technology that administers therapeutic agents directly into the bladder for the targeted treatment of bladder cancer. The platform was designed to deliver drugs such as erdafitinib directly to bladder tumors, enabling localized treatment of non-muscle-invasive bladder cancer including tumors carrying FGFR mutations with reduced systemic exposure.
Differentiator
Problem solved
Functional benefit
Products and services
- Intravesical Delivery Technology (TARIS) A specialized drug delivery technology that administers therapeutic agents directly into the bladder via intravesical delivery, enabling targeted treatment for bladder cancer patients, particularly those with non-muscle-invasive bladder cancer carrying FGFR mutations. The platform forms the foundation for J&J pipeline products including Erda-iDRS and Inlexzo.
Quantifiable outcome
- 89% complete response rate after 18 months
Companies that use TARIS Biomedical
Customer profileSegments1 record
Ideal customer profiles1 record
TARIS Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
TARIS Biomedical partnerships and signals
Strategic signalScale indicators1 record
TARIS Biomedical competitors and assessment
Company assessmentDirect peers
- UroGen Pharma: UroGen develops intravesical therapies for urological cancers, most notably Jelmyto for low-grade upper tract urothelial carcinoma. It is the closest direct competitor in intravesical drug delivery for genitourinary oncology.
Broad incumbents
- Merck & Co. Merck markets Keytruda for BCG-unresponsive NMIBC and is a dominant incumbent in bladder cancer immunotherapy. It competes with TARIS-derived products for the same non-muscle-invasive bladder cancer patient population.
- Bristol-Myers Squibb: BMS markets Opdivo for NMIBC and was an investor in TARIS. It operates in the same bladder cancer treatment space and represents both a competitive threat and a former strategic counterparty.
- Astellas Pharma: Astellas is a leader in urologic oncology with Padcev (enfortumab vedotin) for advanced urothelial carcinoma. It targets the same bladder cancer patient population with overlapping mechanisms and commercial reach.
- Pfizer: Pfizer has a meaningful bladder cancer franchise including Bavencio (co-marketed with Merck KGaA) and broader oncology infrastructure. It competes for market share in NMIBC and adjacent urothelial indications.
- Roche / Genentech: Roche has a broad oncology portfolio and investigational agents in bladder cancer. As a top global oncology player, it represents a broad incumbent competitor and potential strategic counterparty in urologic oncology.
Emerging players
- Incyte Corporation: Incyte developed pemigatinib (Pemazyre), an FGFR inhibitor for cholangiocarcinoma and other FGFR-driven tumors. It is comparable as a developer of selective FGFR-targeted therapies that could be relevant to bladder cancer.
- Taiho Pharmaceutical: Taiho developed futibatinib (Lytgobi), a covalent FGFR inhibitor approved for cholangiocarcinoma. It is a relevant peer in the FGFR inhibitor space that could compete or partner in FGFR-driven bladder cancer.
- Lipella Pharmaceuticals: Lipella is developing intravesical therapies including liposomal formulations for bladder conditions. It is comparable as a small-cap company focused on intravesical drug delivery technology for urological indications.
- Theralase Technologies: Theralase develops intravesical photodynamic therapy for non-muscle-invasive bladder cancer. It represents an emerging alternative non-systemic modality for treating NMIBC patients.
Market position
Customer concentration
TARIS Biomedical social profiles
Digital presenceTARIS Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
TARIS Biomedical leadership team
Management profileNumber of profiles
Profiles4 records
TARIS Biomedical funding detail
Funding detailFunding overview
Funding rounds9 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TARIS Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TARIS Biomedical
What does TARIS Biomedical do?
TARIS Biomedical developed a proprietary intravesical drug delivery technology that administers therapeutic agents directly into the bladder for the targeted treatment of bladder cancer. The platform was designed to deliver drugs such as erdafitinib directly to bladder tumors, enabling localized treatment of non-muscle-invasive bladder cancer including tumors carrying FGFR mutations with reduced systemic exposure.
Is TARIS Biomedical a public or private company?
TARIS Biomedical is a private company. It is classified as corporate owned and is currently acquired.
When was TARIS Biomedical founded?
TARIS Biomedical was founded in 2008. It employs 11 to 50 people.
Where is TARIS Biomedical based?
TARIS Biomedical is headquartered in Lexington, United States, in the North America region.
Who are TARIS Biomedical's main competitors?
UroGen Pharma is listed as a direct peer. Broad incumbents are Merck & Co., Bristol-Myers Squibb, Astellas Pharma, Pfizer and Roche / Genentech. Emerging players are Incyte Corporation, Taiho Pharmaceutical, Lipella Pharmaceuticals and Theralase Technologies.
Does TARIS Biomedical have an API?
No public API is recorded for TARIS Biomedical.
What industry is TARIS Biomedical in?
TARIS Biomedical's product category is Urologic Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAKAOAB, Urologic Oncology. Its NAICS code is 325411 and its SIC code is 3841.